Cubist Pharmaceuticals Inc. (NASDAQ:CBST) has stopped a mid-stage trial of one of its pipeline candidates, CB-500,929 (ecallantide). The drug was being studied for lowering blood loss in patients undergoing cardiac surgery using cardiopulmonary bypass (CPB).  The decision to stop the trial was taken following a review of safety and efficacy data from two phase II trials ...